Abstract

Background

Spinal involvement is a common but serious complication of human brucellosis. However, information on the risk factors associated with spinal involvement in individuals with brucellosis is limited.

Methods

This retrospective case-control study aimed to determine the potential risk factors associated with spinal complications in inpatients with brucellosis.

Results

During the study period, brucellosis was diagnosed in 377 patients, of whom 108 (28.64%) showed spinal involvement. Those with spinal involvement were significantly older than patients in the control group (mean age [standard deviation], 53.25 [10.48] vs 43.12 [13.84] years, respectively; P < .001). The diagnostic delays were significantly longer in patients with spinal involvement than in the control group (mean delay [standard deviation], 11.17 [13.55] vs 6.03 [8.02] weeks; P = .001). Age >40 years (odds ratio, 5.42 [95% confidence interval, 2.65–11.05]; P < .001) and diagnostic delay >4 weeks (2.94 [1.62–5.35]; P < .001) were independently associated with spinal involvement in brucellosis. The lumbar spine at the L3–5 level was the most affected (152 of 249 [61.04%]). Back pain (92 of 108 in case patients vs 21 of 108 in controls; P < .001) and splenomegaly (23 vs 42 of 108, respectively; P = .005) differed significantly between the 2 groups.

Conclusions

Age >40 years and diagnostic delay >4 weeks increased the risk of spinal involvement in brucellosis. Therefore, the time from symptom onset to diagnosis should be shortened, using effective measures to reduce spinal involvement risk.

Brucellosis is one of the most common zoonotic diseases caused by Brucella species [1]. Human brucellosis is a major public health concern in several regions, mainly the Mediterranean region, the Middle East, and parts of Central and South America [2]. Brucellosis affects organs with abundant mononuclear phagocytes, such as the liver, spleen, lymph nodes, and bone marrow [3]. Given its unique pathogenic characteristics, it frequently causes various complications. One serious complication is spinal involvement; brucellosis frequently requires spinal surgery and results in functional sequelae [4].

Approximately 2%–53% of patients with brucellosis demonstrate spinal involvement [5]. A retrospective study in Turkey reported that 39% of patients with brucellosis presented with spondylodiscitis [6]. In Southern Tunisia, 22% of patients had spinal brucellosis diagnosed [7]. Furthermore, 8%–20% of patients with brucellosis presented with spinal involvement in high-risk regions in China [8–10]. Brucellar spondylitis typically occurs in men aged >40 years. On average, patients with spinal involvement are significantly older than those without spinal involvement [5, 9, 10].

Spondylitis mostly affects the lumbar spine, followed by thoracic and cervical regions [11]. The most common complaints of spondylitis include fever, malaise, sweating, back pain, and anorexia. Epidural, paravertebral, prevertebral, and psoas abscesses or radiculitis can occur in brucellar spondylitis. Therefore, correct and early diagnosis and immediate treatment are necessary [12]. Radiological imaging is crucial in evaluating the disease process. Although radiography and computed tomography (CT) may provide some information, magnetic resonance (MR) imaging is highly sensitive in detecting early-stage disease and enlargement in epidural and paravertebral areas.

The clinical and radiological findings of spine-involved brucellosis are mostly atypical and difficult to diagnose because of its nonspecific and variable clinical imaging. Brucellosis is diagnosed late in most patients with vertebral osteomyelitis, with a mean diagnostic delay of 12.7 weeks [13]. At present, the association between diagnostic delay and brucellosis spine involvement remains unreported, and the epidemiological features and risk factors for spinal involvement in patients with brucellosis are largely unknown. Hence, this retrospective case-control study aimed to determine the epidemiological features of and risk factors associated with spinal complications in inpatients with a diagnosis of brucellosis.

METHODS

Study Design

This retrospective case-control study was conducted with a 1:1 case-control ratio at 2 hospitals in Gansu Province, the most brucellosis-endemic area in China. Patients with brucellosis diagnosed at the 940th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army (PLA) and Wuwei People's Hospital between January 2018 and July 2023 were enrolled; in particular, those in whom radiological or MR imaging showed spinal involvement were included for the case group. For the control group, patients without spinal involvement were randomly selected from the enrolled inpatients during the same period.

Inclusion and Exclusion Criteria and Definitions

Brucella infections were diagnosed based on the positive results of the Rose Bengal plate agglutination test and standard agglutination test results ≥1/100. Isolation of Brucella species from blood samples also led to the diagnosis of Brucella infections. In this study, clinical, radiological, or MR imaging evidence of inflammation in ≥1 vertebra or discitis was defined as spinal brucellosis, whereas any evidence of inflammation in any joint was defined as osteoarticular involvement. Scrotal or epididymal pain with positive ultrasonographic findings indicated the presence of epididymo-orchitis.

The study excluded patients with lumbar disk herniation of undetermined cause and tuberculous vertebra, those without any symptoms diagnosed via screening, and those with insufficient information. Diagnostic delay was defined as the interval between the onset of brucellosis symptoms and the confirmed diagnosis at the healthcare institution. Moreover, patients with a systemic disease duration of <12 months before hospitalization were classified as having acute-subacute brucellosis, and those with a systemic disease duration of >12 months were classified as having chronic brucellosis.

Data Collection

Patients’ demographic characteristics (sex, age, ethnicity, and occupation), contact history (exposure to goats or cattle and a family history of brucellosis), clinical manifestations (clinical signs and symptoms), laboratory parameters, and radiological data were obtained from the hospital information system and clinical examinations. For the laboratory analyses, the following parameters were included: complete blood cell count, urinalysis, blood biochemical examination, erythrocyte sedimentation rate, and C-reactive protein level. As for the radiological data, CT or MR imaging of suspicious areas, echocardiography, scrotal Doppler ultrasonography, and other imaging examinations were conducted according to the patient's symptoms. Two experienced clinicians collected all of these data.

Statistical Analysis

Categorical variables are presented as numbers and percentages, and continuous variables as means with standard deviations. Independent samples t test was used for comparing the means of continuous variables from data with normal distribution, whereas the Mann-Whitney U test was used for comparing continuous variables from data without normal distributions. For the categorical variables, the proportions were compared using χ2 tests. The contingency tables were analyzed using Fisher exact tests.

Stepwise logistic regression analysis was also conducted. Associations with spinal involvement in brucellosis were examined using bivariate analyses. In the bivariate analysis, odds ratios (ORs), 95% confidence intervals (CIs), and P values were calculated using χ2 or Fisher exact tests. All variables with a P value ≤.10 in the bivariate analysis were included in multivariate logistic regression analysis. Forward elimination was conducted using the likelihood ratio test. Logistic regression analysis results are reported as adjusted ORs with 95% CIs. Differences were considered statistically significant at P < .05 (2 sided). All statistical data were analyzed using SPSS 22.0 software (SPSS).

Patient Consent Statement

All included patients provided written informed consent. The study design was approved by the local ethics committee (Ethics Committee of the 940th Hospital of the Joint Logistic Support Force of the PLA; protocol no. 2022KYLL056).

RESULTS

During the study period, 377 patients, including 202 from the 940th Hospital of the Joint Logistic Support Force of PLA and 175 from Wuwei People's Hospital, received a diagnosis of brucellosis. Figure 1 illustrates the patient enrollment process. Spinal brucellosis was detected in 108 patients (28.64%).

Flowchart of patient enrollment in the study.
Figure 1.

Flowchart of patient enrollment in the study.

Epidemiological Features of Spinal Involvement in Brucellosis

Table 1 presents the demographic characteristics of the case and control groups. The case group was significantly older (mean age [standard deviation (SD)], 53.25 [10.48] vs 43.12 [13.84] years in the control group; P < .001) and had a significantly longer mean diagnostic delay (11.17 [13.55] vs 6.03 [8.02] weeks, respectively; P = .001). Figure 2 depicts the age and diagnostic delay distributions of the case and control groups; 87.96% of the case patients were >40 years old, and 56.48% had a diagnostic delay >4 weeks. Other demographic characteristics did not differ significantly between the 2 groups.

Age (A) and diagnostic delay (B) distributions in the case and control groups.
Figure 2.

Age (A) and diagnostic delay (B) distributions in the case and control groups.

Table 1.

Demographic and Epidemiological Characteristics in the Case and Control Groups

CharacteristicPatients, No. (%)aP Value
Case Group (n = 108)Control Group (n = 108)
Age, mean (SD), y53.25 (10.48)43.12 (13.84)<.001
Sex
 Male82 (75.93)87 (80.56).41
 Female26 (24.07)21 (19.44)
Ethnicity
 Han96 (88.89)98 (90.74).93
 Dongxiang5 (4.63)4 (3.70)
 Hui5 (4.63)5 (4.63)
 Other2 (1.85)1 (0.93)
Occupation
 Animal herder105 (97.22)97 (89.81).050
 Other3 (2.78)11 (10.19)
Hypertension6 (5.56)12 (11.11).14
Diabetes6 (5.56)12 (11.11).14
Coronary heart disease2 (1.85)1 (0.93)>.99
Smoking8 (7.41)14 (12.96).18
Alcohol1 (0.93)2 (1.85)>.99
Animal exposure
 Sheep60 (55.56)57 (52.78).68
 Cattle40 (37.04)40 (37.04)>.99
Family history of brucellosis infection4 (3.70)3 (2.78)>.99
Clinical type
 Acute and subacute98 (90.74)103 (95.37).28
 Chronic10 (9.26)5 (4.63)
Time from symptom onset to diagnosis, mean (SD), wk11.17 (13.55)6.03 (8.02).001
CharacteristicPatients, No. (%)aP Value
Case Group (n = 108)Control Group (n = 108)
Age, mean (SD), y53.25 (10.48)43.12 (13.84)<.001
Sex
 Male82 (75.93)87 (80.56).41
 Female26 (24.07)21 (19.44)
Ethnicity
 Han96 (88.89)98 (90.74).93
 Dongxiang5 (4.63)4 (3.70)
 Hui5 (4.63)5 (4.63)
 Other2 (1.85)1 (0.93)
Occupation
 Animal herder105 (97.22)97 (89.81).050
 Other3 (2.78)11 (10.19)
Hypertension6 (5.56)12 (11.11).14
Diabetes6 (5.56)12 (11.11).14
Coronary heart disease2 (1.85)1 (0.93)>.99
Smoking8 (7.41)14 (12.96).18
Alcohol1 (0.93)2 (1.85)>.99
Animal exposure
 Sheep60 (55.56)57 (52.78).68
 Cattle40 (37.04)40 (37.04)>.99
Family history of brucellosis infection4 (3.70)3 (2.78)>.99
Clinical type
 Acute and subacute98 (90.74)103 (95.37).28
 Chronic10 (9.26)5 (4.63)
Time from symptom onset to diagnosis, mean (SD), wk11.17 (13.55)6.03 (8.02).001

Abbreviation: SD, standard deviation.

aData represent no. (%) of participants unless otherwise specified.

Table 1.

Demographic and Epidemiological Characteristics in the Case and Control Groups

CharacteristicPatients, No. (%)aP Value
Case Group (n = 108)Control Group (n = 108)
Age, mean (SD), y53.25 (10.48)43.12 (13.84)<.001
Sex
 Male82 (75.93)87 (80.56).41
 Female26 (24.07)21 (19.44)
Ethnicity
 Han96 (88.89)98 (90.74).93
 Dongxiang5 (4.63)4 (3.70)
 Hui5 (4.63)5 (4.63)
 Other2 (1.85)1 (0.93)
Occupation
 Animal herder105 (97.22)97 (89.81).050
 Other3 (2.78)11 (10.19)
Hypertension6 (5.56)12 (11.11).14
Diabetes6 (5.56)12 (11.11).14
Coronary heart disease2 (1.85)1 (0.93)>.99
Smoking8 (7.41)14 (12.96).18
Alcohol1 (0.93)2 (1.85)>.99
Animal exposure
 Sheep60 (55.56)57 (52.78).68
 Cattle40 (37.04)40 (37.04)>.99
Family history of brucellosis infection4 (3.70)3 (2.78)>.99
Clinical type
 Acute and subacute98 (90.74)103 (95.37).28
 Chronic10 (9.26)5 (4.63)
Time from symptom onset to diagnosis, mean (SD), wk11.17 (13.55)6.03 (8.02).001
CharacteristicPatients, No. (%)aP Value
Case Group (n = 108)Control Group (n = 108)
Age, mean (SD), y53.25 (10.48)43.12 (13.84)<.001
Sex
 Male82 (75.93)87 (80.56).41
 Female26 (24.07)21 (19.44)
Ethnicity
 Han96 (88.89)98 (90.74).93
 Dongxiang5 (4.63)4 (3.70)
 Hui5 (4.63)5 (4.63)
 Other2 (1.85)1 (0.93)
Occupation
 Animal herder105 (97.22)97 (89.81).050
 Other3 (2.78)11 (10.19)
Hypertension6 (5.56)12 (11.11).14
Diabetes6 (5.56)12 (11.11).14
Coronary heart disease2 (1.85)1 (0.93)>.99
Smoking8 (7.41)14 (12.96).18
Alcohol1 (0.93)2 (1.85)>.99
Animal exposure
 Sheep60 (55.56)57 (52.78).68
 Cattle40 (37.04)40 (37.04)>.99
Family history of brucellosis infection4 (3.70)3 (2.78)>.99
Clinical type
 Acute and subacute98 (90.74)103 (95.37).28
 Chronic10 (9.26)5 (4.63)
Time from symptom onset to diagnosis, mean (SD), wk11.17 (13.55)6.03 (8.02).001

Abbreviation: SD, standard deviation.

aData represent no. (%) of participants unless otherwise specified.

Factors Associated With Spinal Involvement

Bivariate analysis revealed that spinal involvement in brucellosis was associated with age >40 years, employment as an animal herder, and diagnostic delay >4 weeks. In the multivariate logistic regression model (Table 2), only age >40 years (OR, 5.42, [95% CI, 2.65–11.05]; P < .001) and diagnostic delay >4 weeks (2.94 [1.62–5.35]; P < .001) were found to be independently associated with spinal involvement in brucellosis.

Table 2.

Risk Factors for Spinal Involvement in Brucellosis

Risk FactorPatients, No. (%)Univariate AnalysisMultivariate Analysis
Case Group (n = 108)Control Group (n = 108)OR (95% CI)P ValueOR (95% CI)P Value
Age      
 >40 y95 (87.96)61(56.48)5.63
(2.82–11.26)
<.0015.42
(2.65–11.05)
<.001
 ≤40 y13 (12.04)47 (43.52)
Occupation
 Animal herder105 (97.22)97 (89.81)3.97
(1.07–14.65)
.050
 Other3 (2.78)11 (10.19)
Diagnostic delay
 >4 wk61 (56.48)32 (29.63)3.08
(1.76–5.41)
<.0012.94
(1.62–5.35
<.001
 
 ≤4 wk47 (43.52)76 (70.37)
Risk FactorPatients, No. (%)Univariate AnalysisMultivariate Analysis
Case Group (n = 108)Control Group (n = 108)OR (95% CI)P ValueOR (95% CI)P Value
Age      
 >40 y95 (87.96)61(56.48)5.63
(2.82–11.26)
<.0015.42
(2.65–11.05)
<.001
 ≤40 y13 (12.04)47 (43.52)
Occupation
 Animal herder105 (97.22)97 (89.81)3.97
(1.07–14.65)
.050
 Other3 (2.78)11 (10.19)
Diagnostic delay
 >4 wk61 (56.48)32 (29.63)3.08
(1.76–5.41)
<.0012.94
(1.62–5.35
<.001
 
 ≤4 wk47 (43.52)76 (70.37)

Abbreviations: CI, confidence interval; OR, odds ratio.

Table 2.

Risk Factors for Spinal Involvement in Brucellosis

Risk FactorPatients, No. (%)Univariate AnalysisMultivariate Analysis
Case Group (n = 108)Control Group (n = 108)OR (95% CI)P ValueOR (95% CI)P Value
Age      
 >40 y95 (87.96)61(56.48)5.63
(2.82–11.26)
<.0015.42
(2.65–11.05)
<.001
 ≤40 y13 (12.04)47 (43.52)
Occupation
 Animal herder105 (97.22)97 (89.81)3.97
(1.07–14.65)
.050
 Other3 (2.78)11 (10.19)
Diagnostic delay
 >4 wk61 (56.48)32 (29.63)3.08
(1.76–5.41)
<.0012.94
(1.62–5.35
<.001
 
 ≤4 wk47 (43.52)76 (70.37)
Risk FactorPatients, No. (%)Univariate AnalysisMultivariate Analysis
Case Group (n = 108)Control Group (n = 108)OR (95% CI)P ValueOR (95% CI)P Value
Age      
 >40 y95 (87.96)61(56.48)5.63
(2.82–11.26)
<.0015.42
(2.65–11.05)
<.001
 ≤40 y13 (12.04)47 (43.52)
Occupation
 Animal herder105 (97.22)97 (89.81)3.97
(1.07–14.65)
.050
 Other3 (2.78)11 (10.19)
Diagnostic delay
 >4 wk61 (56.48)32 (29.63)3.08
(1.76–5.41)
<.0012.94
(1.62–5.35
<.001
 
 ≤4 wk47 (43.52)76 (70.37)

Abbreviations: CI, confidence interval; OR, odds ratio.

Clinical Characteristics of Spinal Involvement in Brucellosis

Figure 3 illustrates the involvement of a single vertebral body, where the lumbar region was the most frequently involved vertebral level (203 of 249 [81.53%]), followed by the sacral (23 of 249 [9.24%]), thoracic (17 of 249 [6.83%]), and cervical (6 of 249 [2.41%]) regions. The lumbar spine was the most affected at the L3–5 level (152 of 249 [61.04%]). Spondylodiscitis complications included paravertebral abscess, psoas abscess, and sacral canal cysts or intraspinal cysts in 35 (32.41%), 13 (12.04%), and 16 (14.81%) of the patients, respectively. Figures 4 and 5 show the typical MR imaging and CT findings exhibiting spinal brucellosis. Sagittal T1- and T2-weighted images display vertebral body hypointensity and slight hyperintensity, respectively, and T2-weighted fat-suppression images show hyperintensity in the infected vertebrae.

Distribution of vertebral involvement by vertebrae according to radiological imaging in spinal brucellosis.
Figure 3.

Distribution of vertebral involvement by vertebrae according to radiological imaging in spinal brucellosis.

Magnetic resonance (MR) imaging and computed tomographic (CT) results on a 49-year-old man with spinal brucellosis. Sagittal T1-weighted (A, E) and T2-weighted (B, F) MR images show T9, T10, L2, L3, L4, and L5 vertebral body hypointensity and slight hyperintensity, respectively. C, G, T2-weighted fat-suppression images display hyperintensity in the infected vertebrae. D, H, CT sagittal reconstruction shows T9, T10, L2, L3, L4, and L5 vertebral body destruction and intervertebral space narrowing caused by infection.
Figure 4.

Magnetic resonance (MR) imaging and computed tomographic (CT) results on a 49-year-old man with spinal brucellosis. Sagittal T1-weighted (A, E) and T2-weighted (B, F) MR images show T9, T10, L2, L3, L4, and L5 vertebral body hypointensity and slight hyperintensity, respectively. C, G, T2-weighted fat-suppression images display hyperintensity in the infected vertebrae. D, H, CT sagittal reconstruction shows T9, T10, L2, L3, L4, and L5 vertebral body destruction and intervertebral space narrowing caused by infection.

Magnetic resonance (MR) imaging and computed tomographic (CT) results in a 57-year-old man with spinal brucellosis. A–C, Sagittal T1-weighted (A) and T2-weighted (B) and T2-weighted fat-suppression (C) MR images show multiple abnormal signals in L3, L4, L5, and S1 vertebral body levels. D, CT sagittal reconstruction indicated L3 and L4 vertebral body destruction and intervertebral space narrowing.
Figure 5.

Magnetic resonance (MR) imaging and computed tomographic (CT) results in a 57-year-old man with spinal brucellosis. A–C, Sagittal T1-weighted (A) and T2-weighted (B) and T2-weighted fat-suppression (C) MR images show multiple abnormal signals in L3, L4, L5, and S1 vertebral body levels. D, CT sagittal reconstruction indicated L3 and L4 vertebral body destruction and intervertebral space narrowing.

Table 3 presents the clinical symptoms in the case and control groups. The most common complaints in the case group were back pain (n = 92 [85.19%]), fatigue (n = 64 [59.26%]), sweating (n = 62 [57.41%]), fever (n = 60 [55.56%]), and arthralgia (n = 50 [46.30%]). Back pain (92 of 108 in the case group vs 21 of 108 in the control group; P < .001), sweating (62 vs 46 of 108, respectively; P = .03), arthralgia (50 vs 67 of 108; P = .02), myalgia (29 of 105 vs 43 of 108; P = .04), cough (8 vs 18 of 108; P = .04), and splenomegaly (23 vs 42 of 108; P = .005) differed significantly between the 2 groups.

Table 3.

Clinical Symptoms in the Case and Control Groups

SymptomPatients, No. (%)P Value
Case Group (n = 108)Control Group (n = 108)
Back pain92 (85.19)21 (19.44)<.001
Fatigue64 (59.26)70 (64.81).40
Sweating62 (57.41)46 (42.59).03
Fever60 (55.56)68 (62.96).27
Arthralgia50 (46.30)67 (62.04).02
Myalgia29 (26.85)43 (39.81).04
Chills25 (23.14)24 (22.22).87
Anorexia25 (23.15)17 (15.74).17
Nausea12 (11.11)5 (4.63).08
Headache10 (9.26)13 (12.04).51
Dizziness9 (8.33)11 (10.19).64
Cough8 (7.41)18 (16.67).04
Dyspnea4 (3.70)3 (2.78).70
Abdominal pain5 (4.63)4 (3.70).73
Scrotal pain2 (1.85)6 (5.56).15
Lymphadenopathy12 (11.11)11 (10.19).82
Splenomegaly23 (21.30)42 (38.89).005
Hepatomegaly2 (1.85)3 (2.78).65
SymptomPatients, No. (%)P Value
Case Group (n = 108)Control Group (n = 108)
Back pain92 (85.19)21 (19.44)<.001
Fatigue64 (59.26)70 (64.81).40
Sweating62 (57.41)46 (42.59).03
Fever60 (55.56)68 (62.96).27
Arthralgia50 (46.30)67 (62.04).02
Myalgia29 (26.85)43 (39.81).04
Chills25 (23.14)24 (22.22).87
Anorexia25 (23.15)17 (15.74).17
Nausea12 (11.11)5 (4.63).08
Headache10 (9.26)13 (12.04).51
Dizziness9 (8.33)11 (10.19).64
Cough8 (7.41)18 (16.67).04
Dyspnea4 (3.70)3 (2.78).70
Abdominal pain5 (4.63)4 (3.70).73
Scrotal pain2 (1.85)6 (5.56).15
Lymphadenopathy12 (11.11)11 (10.19).82
Splenomegaly23 (21.30)42 (38.89).005
Hepatomegaly2 (1.85)3 (2.78).65
Table 3.

Clinical Symptoms in the Case and Control Groups

SymptomPatients, No. (%)P Value
Case Group (n = 108)Control Group (n = 108)
Back pain92 (85.19)21 (19.44)<.001
Fatigue64 (59.26)70 (64.81).40
Sweating62 (57.41)46 (42.59).03
Fever60 (55.56)68 (62.96).27
Arthralgia50 (46.30)67 (62.04).02
Myalgia29 (26.85)43 (39.81).04
Chills25 (23.14)24 (22.22).87
Anorexia25 (23.15)17 (15.74).17
Nausea12 (11.11)5 (4.63).08
Headache10 (9.26)13 (12.04).51
Dizziness9 (8.33)11 (10.19).64
Cough8 (7.41)18 (16.67).04
Dyspnea4 (3.70)3 (2.78).70
Abdominal pain5 (4.63)4 (3.70).73
Scrotal pain2 (1.85)6 (5.56).15
Lymphadenopathy12 (11.11)11 (10.19).82
Splenomegaly23 (21.30)42 (38.89).005
Hepatomegaly2 (1.85)3 (2.78).65
SymptomPatients, No. (%)P Value
Case Group (n = 108)Control Group (n = 108)
Back pain92 (85.19)21 (19.44)<.001
Fatigue64 (59.26)70 (64.81).40
Sweating62 (57.41)46 (42.59).03
Fever60 (55.56)68 (62.96).27
Arthralgia50 (46.30)67 (62.04).02
Myalgia29 (26.85)43 (39.81).04
Chills25 (23.14)24 (22.22).87
Anorexia25 (23.15)17 (15.74).17
Nausea12 (11.11)5 (4.63).08
Headache10 (9.26)13 (12.04).51
Dizziness9 (8.33)11 (10.19).64
Cough8 (7.41)18 (16.67).04
Dyspnea4 (3.70)3 (2.78).70
Abdominal pain5 (4.63)4 (3.70).73
Scrotal pain2 (1.85)6 (5.56).15
Lymphadenopathy12 (11.11)11 (10.19).82
Splenomegaly23 (21.30)42 (38.89).005
Hepatomegaly2 (1.85)3 (2.78).65

Table 4 presents other complications in the case and control groups. Sixty-eight patients (62.96%) experienced other complications. The most common complications were skeletal system complications (n = 31 [28.70%]), followed by genitourinary (n = 20 [18.52%]), respiratory (n = 16 [14.81%]), gastrointestinal (n = 16 [14.81%]), and cardiovascular (n = 7 [6.48%]) complications. In the case group, renal (17 vs 5 of 108; P = .007) and hepatic cysts (14 vs 5 of 108; P = .03) were more common.

Table 4.

Other Complications in the Case and Control Groups

ComplicationPatients, No. (%)P Value
Case Group (n = 108)Control Group (n = 108)
Skeletal system
 Sacroiliitis7 (6.48)4 (3.70).35
 Peripheral arthritis26 (24.07)22 (20.37).51
 Osteomyelitis7 (6.48)7 (6.48)>.99
Genitourinary system
 Orchitis2 (1.85)7 (6.48).09
 Epididymitis3 (2.78)7 (6.48).20
 Scrotal swelling2 (1.85)2 (1.85)>.99
 Renal cyst17 (15.74)5 (4.63).007
Respiratory system
 Pneumonia9 (8.33)10 (9.26).81
 Pleural adhesion12 (11.11)9 (8.33).49
 Pleural effusion5 (4.63)5 (4.63)>.99
Cardiovascular system
 Carditis01 (0.93)>.99
 Pericardial effusion7 (6.48)7 (6.48)>.99
Gastrointestinal system
 Cholestasis3 (2.78)4 (3.70).70
 Hepatic cyst14 (12.96)5 (4.63).03
 Ascites02 (1.85).50
ComplicationPatients, No. (%)P Value
Case Group (n = 108)Control Group (n = 108)
Skeletal system
 Sacroiliitis7 (6.48)4 (3.70).35
 Peripheral arthritis26 (24.07)22 (20.37).51
 Osteomyelitis7 (6.48)7 (6.48)>.99
Genitourinary system
 Orchitis2 (1.85)7 (6.48).09
 Epididymitis3 (2.78)7 (6.48).20
 Scrotal swelling2 (1.85)2 (1.85)>.99
 Renal cyst17 (15.74)5 (4.63).007
Respiratory system
 Pneumonia9 (8.33)10 (9.26).81
 Pleural adhesion12 (11.11)9 (8.33).49
 Pleural effusion5 (4.63)5 (4.63)>.99
Cardiovascular system
 Carditis01 (0.93)>.99
 Pericardial effusion7 (6.48)7 (6.48)>.99
Gastrointestinal system
 Cholestasis3 (2.78)4 (3.70).70
 Hepatic cyst14 (12.96)5 (4.63).03
 Ascites02 (1.85).50
Table 4.

Other Complications in the Case and Control Groups

ComplicationPatients, No. (%)P Value
Case Group (n = 108)Control Group (n = 108)
Skeletal system
 Sacroiliitis7 (6.48)4 (3.70).35
 Peripheral arthritis26 (24.07)22 (20.37).51
 Osteomyelitis7 (6.48)7 (6.48)>.99
Genitourinary system
 Orchitis2 (1.85)7 (6.48).09
 Epididymitis3 (2.78)7 (6.48).20
 Scrotal swelling2 (1.85)2 (1.85)>.99
 Renal cyst17 (15.74)5 (4.63).007
Respiratory system
 Pneumonia9 (8.33)10 (9.26).81
 Pleural adhesion12 (11.11)9 (8.33).49
 Pleural effusion5 (4.63)5 (4.63)>.99
Cardiovascular system
 Carditis01 (0.93)>.99
 Pericardial effusion7 (6.48)7 (6.48)>.99
Gastrointestinal system
 Cholestasis3 (2.78)4 (3.70).70
 Hepatic cyst14 (12.96)5 (4.63).03
 Ascites02 (1.85).50
ComplicationPatients, No. (%)P Value
Case Group (n = 108)Control Group (n = 108)
Skeletal system
 Sacroiliitis7 (6.48)4 (3.70).35
 Peripheral arthritis26 (24.07)22 (20.37).51
 Osteomyelitis7 (6.48)7 (6.48)>.99
Genitourinary system
 Orchitis2 (1.85)7 (6.48).09
 Epididymitis3 (2.78)7 (6.48).20
 Scrotal swelling2 (1.85)2 (1.85)>.99
 Renal cyst17 (15.74)5 (4.63).007
Respiratory system
 Pneumonia9 (8.33)10 (9.26).81
 Pleural adhesion12 (11.11)9 (8.33).49
 Pleural effusion5 (4.63)5 (4.63)>.99
Cardiovascular system
 Carditis01 (0.93)>.99
 Pericardial effusion7 (6.48)7 (6.48)>.99
Gastrointestinal system
 Cholestasis3 (2.78)4 (3.70).70
 Hepatic cyst14 (12.96)5 (4.63).03
 Ascites02 (1.85).50

Table 5 presents the laboratory features of the 2 groups. The case group had significantly higher erythrocyte sedimentation rate (mean [SD], 39.53 [29.18] vs 14.73 [18.83] mm/h in the control group; P < .001), platelet count (220.58 × 109/L [81.90 × 109/L] vs 180.92 × 109/L [61.67 × 109/L], respectively; P = .003), platelet-lymphocyte ratio (137.83 [63.05] vs 114.19 [52.99]; P = .048), and γ-glutamyl transferase level (57.16 [44.97] vs 37.91 [31.24] IU/L; P = .007) and significantly lower albumin-globulin ratio (1.17 [0.26] vs 1.30 [0.30]; P = .001) and serum creatinine level (57.32 [14.93] vs 65.82 [17.06] μmol/L; P = .004). In addition, 16 blood cultures from both groups were positive, and the isolates were identified as types of Brucella melitensis.

Table 5.

Laboratory Features of the Case and Control Groups

MeasurementLaboratory Value, Mean (SD)aP Value
Case Group (n = 108)Control Group (n = 108)
Standard agglutination test, titer1/2001/200.76
Erythrocyte sedimentation rate, mm/h39.53 (29.18)14.73 (18.83)<.001
C-reactive protein, mg/L26.11 (32.12)24.85 33.94).85
Procalcitonin, ng/mL0.18 (0.21)0.36 (0.77).16
Interleukin 6, pg/mL35.955 (2.26)63.67 (209.03).433
Blood cell count, ×109/L
 Red blood cells4.56 (0.64)4.63 (0.54).57
 White blood cells5.70 (1.65)5.38 (2.01).34
 Neutrophils3.41 (1.27)2.97 (1.67).11
 Lymphocytes1.75 0.62)1.86 (0.87).41
 Monocytes0.45 0.18)0.43 (0.21).55
 Eosinophils0.07 (0.06)0.09 0.09).17
 Basophils0.02 (0.01)0.02 (0.02).19
 Platelets220.58 (81.90)180.92 (61.67).003
Hemoglobin, g/L134.58 (17.51)137.95 18.75).31
Neutrophil-lymphocyte ratio2.17 (1.26)2.11 (1.80).85
Platelet-lymphocyte ratio137.83 (63.05)114.195 (2.99).048
Monocyte-lymphocyte ratio0.28 (0.14)0.270.17).84
Aspartate transaminase, IU/L25.44 (16.51)27.10 (17.01).59
Alanine transaminase, IU/L36.69 (35.81)35.43 (32.22).84
Alkaline phosphatase, IU/L100.59 (38.57)91.94 (62.06).36
γ-Glutamyl transferase, IU/L57.16 (44.97)37.91 (31.24).007
Creatine kinase, umol/L55.62 (44.64)59.82 (37.18).64
Creatine kinase isoenzyme, IU/L15.21 (22.20)16.47 (30.19).81
α-Hydroxybutyric dehydrogenase, IU/L166.48 (43.65)198.08 (118.85).07
Lactate dehydrogenase, IU/L180.375 (2.51)216.17 (196.66).23
Albumin, g/L34.08 (4.74)35.765 (.45).07
Globulin, g/L31.54 (5.17)30.35 5 (.03).20
Albumin-globulin ratio1.17 (0.26)1.30 (0.30).001
Total bilirubin, μmol/L11.68 (5.79)13.59 (6.20).08
Serum creatinine, μmol/L57.32 (14.93)65.82 (17.06).004
High-density lipoprotein, mmol/L0.76 (0.24)0.77 (0.25).88
Low-density lipoprotein, mmol/L2.24 (0.77)2.26 (0.80).68
Total cholesterol, mmol/L3.55 (1.08)3.64 (1.07).72
Blood culture, no. (%)8 (7.41)8 (7.41)>.99
MeasurementLaboratory Value, Mean (SD)aP Value
Case Group (n = 108)Control Group (n = 108)
Standard agglutination test, titer1/2001/200.76
Erythrocyte sedimentation rate, mm/h39.53 (29.18)14.73 (18.83)<.001
C-reactive protein, mg/L26.11 (32.12)24.85 33.94).85
Procalcitonin, ng/mL0.18 (0.21)0.36 (0.77).16
Interleukin 6, pg/mL35.955 (2.26)63.67 (209.03).433
Blood cell count, ×109/L
 Red blood cells4.56 (0.64)4.63 (0.54).57
 White blood cells5.70 (1.65)5.38 (2.01).34
 Neutrophils3.41 (1.27)2.97 (1.67).11
 Lymphocytes1.75 0.62)1.86 (0.87).41
 Monocytes0.45 0.18)0.43 (0.21).55
 Eosinophils0.07 (0.06)0.09 0.09).17
 Basophils0.02 (0.01)0.02 (0.02).19
 Platelets220.58 (81.90)180.92 (61.67).003
Hemoglobin, g/L134.58 (17.51)137.95 18.75).31
Neutrophil-lymphocyte ratio2.17 (1.26)2.11 (1.80).85
Platelet-lymphocyte ratio137.83 (63.05)114.195 (2.99).048
Monocyte-lymphocyte ratio0.28 (0.14)0.270.17).84
Aspartate transaminase, IU/L25.44 (16.51)27.10 (17.01).59
Alanine transaminase, IU/L36.69 (35.81)35.43 (32.22).84
Alkaline phosphatase, IU/L100.59 (38.57)91.94 (62.06).36
γ-Glutamyl transferase, IU/L57.16 (44.97)37.91 (31.24).007
Creatine kinase, umol/L55.62 (44.64)59.82 (37.18).64
Creatine kinase isoenzyme, IU/L15.21 (22.20)16.47 (30.19).81
α-Hydroxybutyric dehydrogenase, IU/L166.48 (43.65)198.08 (118.85).07
Lactate dehydrogenase, IU/L180.375 (2.51)216.17 (196.66).23
Albumin, g/L34.08 (4.74)35.765 (.45).07
Globulin, g/L31.54 (5.17)30.35 5 (.03).20
Albumin-globulin ratio1.17 (0.26)1.30 (0.30).001
Total bilirubin, μmol/L11.68 (5.79)13.59 (6.20).08
Serum creatinine, μmol/L57.32 (14.93)65.82 (17.06).004
High-density lipoprotein, mmol/L0.76 (0.24)0.77 (0.25).88
Low-density lipoprotein, mmol/L2.24 (0.77)2.26 (0.80).68
Total cholesterol, mmol/L3.55 (1.08)3.64 (1.07).72
Blood culture, no. (%)8 (7.41)8 (7.41)>.99

Abbreviation: SD, standard deviation.

aData represent mean (SD) values unless otherwise specified.

Table 5.

Laboratory Features of the Case and Control Groups

MeasurementLaboratory Value, Mean (SD)aP Value
Case Group (n = 108)Control Group (n = 108)
Standard agglutination test, titer1/2001/200.76
Erythrocyte sedimentation rate, mm/h39.53 (29.18)14.73 (18.83)<.001
C-reactive protein, mg/L26.11 (32.12)24.85 33.94).85
Procalcitonin, ng/mL0.18 (0.21)0.36 (0.77).16
Interleukin 6, pg/mL35.955 (2.26)63.67 (209.03).433
Blood cell count, ×109/L
 Red blood cells4.56 (0.64)4.63 (0.54).57
 White blood cells5.70 (1.65)5.38 (2.01).34
 Neutrophils3.41 (1.27)2.97 (1.67).11
 Lymphocytes1.75 0.62)1.86 (0.87).41
 Monocytes0.45 0.18)0.43 (0.21).55
 Eosinophils0.07 (0.06)0.09 0.09).17
 Basophils0.02 (0.01)0.02 (0.02).19
 Platelets220.58 (81.90)180.92 (61.67).003
Hemoglobin, g/L134.58 (17.51)137.95 18.75).31
Neutrophil-lymphocyte ratio2.17 (1.26)2.11 (1.80).85
Platelet-lymphocyte ratio137.83 (63.05)114.195 (2.99).048
Monocyte-lymphocyte ratio0.28 (0.14)0.270.17).84
Aspartate transaminase, IU/L25.44 (16.51)27.10 (17.01).59
Alanine transaminase, IU/L36.69 (35.81)35.43 (32.22).84
Alkaline phosphatase, IU/L100.59 (38.57)91.94 (62.06).36
γ-Glutamyl transferase, IU/L57.16 (44.97)37.91 (31.24).007
Creatine kinase, umol/L55.62 (44.64)59.82 (37.18).64
Creatine kinase isoenzyme, IU/L15.21 (22.20)16.47 (30.19).81
α-Hydroxybutyric dehydrogenase, IU/L166.48 (43.65)198.08 (118.85).07
Lactate dehydrogenase, IU/L180.375 (2.51)216.17 (196.66).23
Albumin, g/L34.08 (4.74)35.765 (.45).07
Globulin, g/L31.54 (5.17)30.35 5 (.03).20
Albumin-globulin ratio1.17 (0.26)1.30 (0.30).001
Total bilirubin, μmol/L11.68 (5.79)13.59 (6.20).08
Serum creatinine, μmol/L57.32 (14.93)65.82 (17.06).004
High-density lipoprotein, mmol/L0.76 (0.24)0.77 (0.25).88
Low-density lipoprotein, mmol/L2.24 (0.77)2.26 (0.80).68
Total cholesterol, mmol/L3.55 (1.08)3.64 (1.07).72
Blood culture, no. (%)8 (7.41)8 (7.41)>.99
MeasurementLaboratory Value, Mean (SD)aP Value
Case Group (n = 108)Control Group (n = 108)
Standard agglutination test, titer1/2001/200.76
Erythrocyte sedimentation rate, mm/h39.53 (29.18)14.73 (18.83)<.001
C-reactive protein, mg/L26.11 (32.12)24.85 33.94).85
Procalcitonin, ng/mL0.18 (0.21)0.36 (0.77).16
Interleukin 6, pg/mL35.955 (2.26)63.67 (209.03).433
Blood cell count, ×109/L
 Red blood cells4.56 (0.64)4.63 (0.54).57
 White blood cells5.70 (1.65)5.38 (2.01).34
 Neutrophils3.41 (1.27)2.97 (1.67).11
 Lymphocytes1.75 0.62)1.86 (0.87).41
 Monocytes0.45 0.18)0.43 (0.21).55
 Eosinophils0.07 (0.06)0.09 0.09).17
 Basophils0.02 (0.01)0.02 (0.02).19
 Platelets220.58 (81.90)180.92 (61.67).003
Hemoglobin, g/L134.58 (17.51)137.95 18.75).31
Neutrophil-lymphocyte ratio2.17 (1.26)2.11 (1.80).85
Platelet-lymphocyte ratio137.83 (63.05)114.195 (2.99).048
Monocyte-lymphocyte ratio0.28 (0.14)0.270.17).84
Aspartate transaminase, IU/L25.44 (16.51)27.10 (17.01).59
Alanine transaminase, IU/L36.69 (35.81)35.43 (32.22).84
Alkaline phosphatase, IU/L100.59 (38.57)91.94 (62.06).36
γ-Glutamyl transferase, IU/L57.16 (44.97)37.91 (31.24).007
Creatine kinase, umol/L55.62 (44.64)59.82 (37.18).64
Creatine kinase isoenzyme, IU/L15.21 (22.20)16.47 (30.19).81
α-Hydroxybutyric dehydrogenase, IU/L166.48 (43.65)198.08 (118.85).07
Lactate dehydrogenase, IU/L180.375 (2.51)216.17 (196.66).23
Albumin, g/L34.08 (4.74)35.765 (.45).07
Globulin, g/L31.54 (5.17)30.35 5 (.03).20
Albumin-globulin ratio1.17 (0.26)1.30 (0.30).001
Total bilirubin, μmol/L11.68 (5.79)13.59 (6.20).08
Serum creatinine, μmol/L57.32 (14.93)65.82 (17.06).004
High-density lipoprotein, mmol/L0.76 (0.24)0.77 (0.25).88
Low-density lipoprotein, mmol/L2.24 (0.77)2.26 (0.80).68
Total cholesterol, mmol/L3.55 (1.08)3.64 (1.07).72
Blood culture, no. (%)8 (7.41)8 (7.41)>.99

Abbreviation: SD, standard deviation.

aData represent mean (SD) values unless otherwise specified.

Moreover, 17 patients (15.74%) underwent vertebral surgery. The surgical procedure consisted of debridement and posterior pedicle screw fixation based on drug treatment. The prognosis in patients who underwent surgery did not differ significantly from that in nonsurgical cases.

DISCUSSION

Human brucellosis is a major health concern worldwide. Spondylodiscitis is a common but serious complication of brucellosis in humans. This study describes the epidemiological and laboratory findings in patients with spinal involvement in brucellosis, as well as risk factors associated with this condition.

Research on the epidemiological characteristics of spinal brucellosis is currently limited. The present study demonstrated that patients with brucellosis and spinal involvement were significantly older than those without spinal involvement. The prognosis is likely to be unfavorable for older patients, and spondylodiscitis occurs more frequently in adults and older people than in other populations [9, 14]. In the present study, age >40 years was an independent risk factor for spinal involvement in brucellosis. Patients with brucellosis aged >40 years had a 5.42 times greater risk of spinal involvement than those aged ≤40 years.

Diagnostic delay is another reported risk factor for spinal involvement in brucellosis. In the present study, the mean diagnostic delay was significantly longer in patients with spinal involvement than in those without spinal involvement (11.17 vs 6.03 weeks, respectively). Although a previous study reported that patients with osteoarticular disease experienced a greater diagnostic delay than other patients [15], that study lacked a control group. In the present study, a diagnostic delay of >4 weeks increased the risk of developing spinal infections by 2.94 times. This risk may be explained by the higher frequency of spinal brucellosis (28.64%) in the present study compared with other studies [8–10]; moreover, the present study had a longer mean diagnostic delay than other studies in high-risk regions of China.

Owing to its nonspecific clinical signs, human brucellosis is subject to common diagnostic delays [16]. Accordingly, the diagnostic delay is multifactorial. The clinical manifestations of brucellosis are typically nonspecific and include various clinical symptoms, thereby possibly leading to misdiagnosis. A study involving 2060 cases reported that 57.62% of patients with brucellosis were misdiagnosed or suspected of having other diseases with similar clinical symptoms [17]. Delays in diagnosis also result from health service inadequacies and socioeconomic factors. The average diagnostic delay was reported to be shorter in urban areas than in villages [17]. Moreover, older age is associated with a longer diagnostic delay [16]. However, the present study determined that older age and diagnostic delay were both independent risk factors for spinal involvement in brucellosis. Therefore, the risk of spinal involvement in older adults may increase because of diagnostic delays. Patients with brucellar spondylitis appear to respond better to antibiotic therapy with optimal duration and surgical intervention when required [12]. Thus, older people should be given increased attention, and diagnostic capacity should be improved to reduce diagnostic delays and facilitate prompt and appropriate treatment.

Spondylodiscitis mostly affects the lumbosacral region [18]. In the present study, the L3–5 lumbar spine was the most commonly affected region among the enrolled patients. Localized spinal pain is the earliest sign of brucellar spondylitis, and back pain is the most common symptom in patients with spinal involvement. Furthermore, 85.9%–100% of patients with spinal involvement present with back pain [8, 19, 20]. Strengthening health education in the target population is crucial for prevention and control of brucellosis. When individuals in high-risk areas present with back pain, brucellosis should be suspected.

The present study also demonstrated that renal and hepatic cysts were more common in patients with spinal involvement, and their serum creatinine, albumin-globulin ratio, and liver transferase levels differed significantly from those of patients without spinal involvement. This finding might be linked to kidney and liver involvement in brucellosis [21, 22]. Patients with spinal involvement have higher erythrocyte sedimentation rates and platelet counts than those without spinal involvement. Elevated erythrocyte sedimentation rate and platelet count are closely associated with osteoarticular involvement [23, 24]. These 2 factors can be used to estimate the clinical course of brucellosis [25].

The present study had some limitations. For example, selection bias resulting from case and control enrollment is possible. Patient data were collected retrospectively; thus, some records of events provided by the participants might be inaccurate or incomplete. Accordingly, the bias was reduced by selecting participants from 2 hospitals, Wuwei people’s hosptial for a secondary hospital and 940th hospital for a tertiary hospital. Stratified analysis revealed that age >40 years and diagnostic delay >4 weeks were independent risk factors for spinal involvement in brucellosis among patients from both hospitals. Cohort studies are required to demonstrate these relationships as well as intervention effects and pathogenic mechanisms. The relationship between diagnostic delay and other brucellosis complications also needs further exploration.

In summary, age >40 years and diagnostic delay >4 weeks are risk factors for spinal involvement in brucellosis. The risk of spinal involvement increases as the age and diagnostic delay increase. Therefore, diagnostic delays and older age in high-risk areas should be given attention, and diagnostic delays should be shortened, using effective measures to reduce the risk of spinal involvement.

Acknowledgments

The authors thank the patients and their families involved in the study.

Author contributions. Z. P., P. D., and Y. Y. conceived and designed the study, prepared the ethics protocol, and wrote the manuscript. Y. L., M. B., and T. L. enrolled the patients and collected clinical data. J. P. and D. X. verified the underlying data. All authors revised and approved the final version of the manuscript.

Data availability statement. The data sets used or analyzed during the current study are available from the corresponding authors on reasonable request.

Financial support. This work was supported by the Gansu Province Natural Science Foundation (grant 22JR11RA012).

References

1

Lai
 
S
,
Chen
 
Q
,
Li
 
Z
.
Human brucellosis: an ongoing global health challenge
.
China CDC Weekly
 
2021
;
3
:
120
3
.

2

Qureshi
 
KA
,
Parvez
 
A
,
Fahmy
 
NA
, et al.  
Brucellosis: epidemiology, pathogenesis, diagnosis and treatment-a comprehensive review
.
Ann Med
 
2023
;
55
:
2295398
.

3

Laine
 
CG
,
Johnson
 
VE
,
Scott
 
HM
,
Arenas-Gamboa
 
AM
.
Global estimate of human brucellosis incidence
.
Emerging Infect Dis
 
2023
;
29
:
1789
97
.

4

Spernovasilis
 
N
,
Karantanas
 
A
,
Markaki
 
I
, et al.  
Brucella spondylitis: current knowledge and recent advances
.
J Clin Med
 
2024
;
13
:
595
.

5

Esmaeilnejad-Ganji
 
SM
,
Esmaeilnejad-Ganji
 
SMR
.
Osteoarticular manifestations of human brucellosis: a review
.
World J Orthop
 
2019
;
10
:
54
62
.

6

Kazak
 
E
,
Akalın
 
H
,
Yılmaz
 
E
, et al.  
Brucellosis: a retrospective evaluation of 164 cases
.
Singapore Med J
 
2016
;
57
:
624
9
.

7

Koubaa
 
M
,
Maaloul
 
I
,
Marrakchi
 
C
, et al.  
Spinal brucellosis in south of Tunisia: review of 32 cases
.
Spine J
 
2014
;
14
:
1538
44
.

8

Liang
 
C
,
Wei
 
W
,
Liang
 
X
,
De
 
E
,
Zheng
 
B
.
Spinal brucellosis in Hulunbuir, China, 2011–2016
.
Infect Drug Resist
 
2019
;
12
:
1565
71
.

9

Shi
 
Y
,
Gao
 
H
,
Pappas
 
G
, et al.  
Clinical features of 2041 human brucellosis cases in China
.
PloS One
 
2018
;
13
:
e0205500
.

10

Jiang
 
W
,
Chen
 
J
,
Li
 
Q
, et al.  
Epidemiological characteristics, clinical manifestations and laboratory findings in 850 patients with brucellosis in Heilongjiang province, China
.
BMC Infect Dis
 
2019
;
19
:
439
.

11

Turgut
 
M
,
Turgut
 
AT
,
Koşar
 
U
.
Spinal brucellosis: Turkish experience based on 452 cases published during the last century
.
Acta Neurochir (Wien)
 
2006
;
148
:
1033
44
;
discussion 1044
.

12

Turgut
 
M
,
Haddad
 
FS
,
Oreste
 
DD
.
Neurobrucellosis: clinical, diagnostic and therapeutic features
.
Berlin, German
:
Springer
;
2016
.

13

Colmenero
 
JD
,
Ruiz-Mesa
 
JD
,
Plata
 
A
, et al.  
Clinical findings, therapeutic approach, and outcome of brucellar vertebral osteomyelitis
.
Clin Infect Dis
 
2008
;
46
:
426
33
.

14

Keramat
 
F
,
Hashemi
 
SH
,
Esna-ashari
 
F
,
Kaseb
 
K
.
Clinical and para-clinical features of brucellosis with and without spondylodiscitis
.
Avicenna J Clin Microbiol Infect
 
2021
;
8
:
39
44
.

15

Zribi
 
M
,
Ammari
 
L
,
Masmoudi
 
A
,
Tiouiri
 
H
,
Fendri
 
C
.
Clinical manifestations, complications and treatment of brucellosis: 45-patient study [in French]
.
Pathol Biol
 
2009
;
57
:
349
52
.

16

Zhai
 
J
,
Peng
 
R
,
Wang
 
Y
, et al.  
Factors associated with diagnostic delays in human brucellosis in Tongliao city, Inner Mongolia autonomous region, China
.
Front Public Health
 
2021
;
9
:
648054
.

17

Wang
 
Y
,
Zhang
 
W
,
Ke
 
Y
, et al.  
Human brucellosis, a heterogeneously distributed, delayed, and misdiagnosed disease in China
.
Clin Infect Dis
 
2013
;
56
:
750
1
.

18

Turgut
 
M
,
Cullu
 
E
,
Sendur
 
OF
,
Güyrer
 
G
.
Brucellar spine infection—four case reports
.
Neurol Med Chir (Tokyo)
 
2004
;
44
:
562
7
.

19

Ulu-Kilic
 
A
,
Karakas
 
A
,
Erdem
 
H
, et al.  
Update on treatment options for spinal brucellosis
.
Clin Microbiol Infect
 
2014
;
20
:
O75
82
.

20

Solera
 
J
,
Lozano
 
E
,
Martínez-Alfaro
 
E
,
Espinosa
 
A
,
Castillejos
 
ML
,
Abad
 
L
.
Brucellar spondylitis: review of 35 cases and literature survey
.
Clin Infect Dis
 
1999
;
29
:
1440
9
.

21

Akritidis
 
N
,
Tzivras
 
M
,
Delladetsima
 
I
,
Stefanaki
 
S
,
Moutsopoulos
 
HM
,
Pappas
 
G
.
The liver in brucellosis
.
Clin Gastroenterol Hepatol
 
2007
;
5
:
1109
12
.

22

Jin
 
M
,
Fan
 
Z
,
Gao
 
R
,
Li
 
X
,
Gao
 
Z
,
Wang
 
Z
.
Research progress on complications of brucellosis
.
Front Cell Infect Microbiol
 
2023
;
13
:
1136674
.

23

Aktug-Demir
 
N
,
Kolgelier
 
S
,
Ozcimen
 
S
,
Sumer
 
S
,
Demir
 
LS
,
Inkaya
 
AC
.
Diagnostic clues for spondylitis in acute brucellosis
.
Saudi Med J
 
2014
;
35
:
816
20
.

24

Sen
 
P
,
Demirdal
 
T
,
Nemli
 
SA
.
Predictive value of inflammation markers in brucellosis
.
Arch Iran Med
 
2019
;
22
:
640
5
.

25

Okan
 
DH
,
Gökmen
 
Z
,
Seyit
 
B
,
Yuksel
 
K
,
Cevdet
 
Z
,
Deniz
 
A
.
Mean platelet volume in brucellosis: correlation between Brucella standard serum agglutination test results, platelet count, and C-reactive protein
.
Afr Health Sci
 
2014
;
14
:
797
801
.

Author notes

Z. P., Y. L., M. B., and T. L. contributed equally to this work.

P. D. and Y. Y. contributed equally to this work.

Potential conflicts of interest. All authors: No reported conflicts of interest.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.